GlassScriptPhysician profile
Joseph William Beets
NPI 1124070594
$3,148.45
in general payments reported to CMS, 2019-2025
23 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $144 · 2021: $28.38 · 2022: $486 · 2023: $445 · 2024: $473 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,511.80 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.80 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $412.46 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $108.45 | 2019 | |
| Nestle Healthcare Nutrition INC. | $103.72 | 2022-2023 | |
| Celgene Corporation | $75.26 | 2021-2024 | Zeposia |
| Pfizer INC. | $65.29 | 2019-2023 | |
| Lilly USA, LLC | $57.64 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $54.48 | 2024-2025 | Dupixent |
| Shionogi INC | $52.02 | 2019 | |
| Genzyme Corporation | $47.12 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $45.31 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $30.15 | 2024-2025 | Zenpep |
| Organon LLC | $25.31 | 2025 | Hadlima |
| Gilead Sciences, INC. | $22.00 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $17.44 | 2020 | |
| Merck Sharp & Dohme LLC | $16.91 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.06 | 2025 | |
| Madrigal Pharmaceuticals | $15.72 | 2025 | Rezdiffra |
| Allergan, INC. | $13.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $13.20 | 2024 | |
| Janssen Scientific Affairs, LLC | $12.04 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Beets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.